PBAC's latest decision on Mepolizumab: Recommended with restriction (2024). Considered for Treatment of uncontrolled severe asthma (including severe eosinophilic asthma) in patients aged 12 years and over.
PBAC outcome
Recommended with restriction
Authority Required
ICER (AUD/QALY)
Cost-min
cost-minimisation analysis
Submissions
8
first 2016
Submissions
8
2016 → 2024
Eligible population
Adults and adolescents aged ≥12 years with uncontrolled severe asthma receiving optimised asthma therapy (high-dose inhaled corticosteroid plus long-acting beta-2 agonist for at least 12 months).
Therapy area
Respiratory
Line of therapy
Any
Evidence base
Cost-minimisation
Primary endpoint
Cost-minimisation
Comparator
omalizumab
Economic model
Cost-minimisation
ICER note
This is a Category 3 submission (administrative amendment to authority level and clinical criteria). No new economic evaluation was conducted; the original cost-minimisation analysis from July 2016 remains applicable.
Submission history
Mar 2016: Recommended with restriction · Restricted
Jul 2016: Noted · Restricted
Nov 2017: Noted · Restricted
Mar 2018: Noted · Restricted
Mar 2020: Recommended with restriction · Restricted
Nov 2021: Recommended with restriction · Authority Required
Nov 2022: Recommended with restriction · Authority Required
Mar 2024: Recommended with restriction · Authority Required